■侵袭性真菌感染(FI)与显著的发病率和死亡率相关。这项工作的目的是比较每位成年患者的费用,与静脉注射伊沙康康唑(ISAV),然后口服ISAV相比,脂质体两性霉素B,然后泊沙康唑(L-AMB→POSA)的方案用于治疗国际金融机构。比较是从西班牙国家卫生系统(SNS)的角度进行的。
■由于间接比较证明了比较者之间的相似功效,采取了成本最小化的方法。获取药物,administration,住院治疗,从SNS角度评估实验室检查和不良事件费用.进行了确定性和概率敏感性分析。
■每位患者的总费用为ISAV的24,715.54欧元,而L-AMB→POSA的29,753.53欧元,导致每位接受ISAV治疗的患者节省费用5,037.99欧元(-16.9%)。在所有敏感性分析中,ISAV的治疗费用仍然低于L-AMB→POSA(-7,968.89€至-326.59€),治疗持续时间是最有影响的参数。
■根据目前的模型,与L-AMB→POSA相比,用ISAV治疗IFIs会节省SNS。这些节省归因于IV治疗的持续时间较短,使用ISAV时,减少了医疗保健资源的使用,并降低了与管理不良反应相关的成本。
UNASSIGNED: Invasive fungal infections (IFI) are associated with significant morbidity and mortality. The objective of this work was to compare the costs per adult patient, associated with intravenous isavuconazole (ISAV) followed by oral ISAV versus the regimen of liposomal amphotericin B followed by posaconazole (L-AMB→POSA) in the treatment of IFI. The comparison was conducted from the perspective of the Spanish National Health System (SNS).
UNASSIGNED: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration, hospitalization, laboratory tests and adverse events costs were evaluated from SNS perspective. Deterministic and probabilistic sensitivity analyzes were performed.
UNASSIGNED: Total costs per-patient were €24,715.54 with ISAV versus €29,753.53 with L-AMB→POSA, resulting in cost-savings per patient treated with ISAV of €5,037.99 (-16.9%). Treatment costs of IFI remained lower for ISAV than for L-AMB→POSA across all sensitivity analyses (-7,968.89€ to -326.59€), being treatment duration the most influential parameter.
UNASSIGNED: According to the present model, the treatment of IFIs with ISAV would generate savings for the SNS compared to L-AMB→POSA. These savings are attributed to the shorter duration of IV treatment, reduced use of healthcare resources and lower costs associated with managing adverse effects when ISAV was employed.